#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
BookmarkClick here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved....
Read MoreMay 27, 2023
BookmarkClick here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved....
Read MoreMay 21, 2023
Bookmark1. In this randomized controlled trial, respiratory syncytial virus prefusion F...
Read MoreMay 9, 2023
BookmarkClick here to read this study in JAMA
Read MoreMay 6, 2023
BookmarkClick here to read this study in NEJM
Read MoreMay 3, 2023
Click to read this study in JAMA Network Open.
Read MoreApr 24, 2023
1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group...
Read MoreApr 24, 2023
1. In asymptomatic patients, subclinical coronary atherosclerosis was associated with an...
Read MoreApr 7, 2023
Click to read this study in The Lancet Oncology.
Read MoreMar 31, 2023
1. In this randomized controlled trial, among patients with recurrent kidney stones,...
Read MoreMar 26, 2023
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared...
Read MoreMar 24, 2023
1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior...
Read MoreMar 20, 2023
Click to read this study in JAMA Surgery.
Read MoreMar 20, 2023
Click to read this study in The Lancet Oncology.
Read MoreMar 20, 2023
1. Patients allocated to the sotorasib group reported increased progression-free survival compared...
Read MoreMar 20, 2023
1. In this randomized clinical trial, among 167 older adults with frailty and non-ST segment...
Read MoreMar 10, 2023
Click to read this study in The Lancet Oncology.
Read MoreMar 10, 2023
Click to read this study in JAMA Network Open.
Read MoreMar 10, 2023
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the...
Read MoreMar 10, 2023
1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both...
Read MoreFeb 21, 2023
Click here to read this study in NEJM
Read More